# CapsiAtra (Dihydrocapsiate)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/capsiatra
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-24
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Dihydrocapsiate, DHC, 8-Methylnonanoic acid vanillyl ester, Non-pungent capsaicinoid, CH-19 Sweet pepper extract, Vanillyl 8-methylnonanoate

## Overview

CapsiAtra (dihydrocapsiate) is a non-pungent capsaicinoid compound derived from sweet peppers that activates TRPV1 receptors to enhance [thermogenesis](/ingredients/condition/weight-management). Clinical research indicates it may increase resting energy expenditure by approximately 50 kcal/day without causing gastrointestinal irritation.

## Health Benefits

• Increases resting energy expenditure by 50 kcal/day (based on one small RCT, n=12)
• Stimulates fat oxidation through TRPV1 receptor activation (mechanism-based evidence)
• Boosts basal metabolism without gastrointestinal irritation (limited clinical evidence)
• May support weight management efforts (preliminary evidence from one 4-week trial)
• Enhances [thermogenesis](/ingredients/condition/weight-management) without the pungency of capsaicin (mechanistic studies only)

## Mechanism of Action

CapsiAtra activates transient receptor potential vanilloid 1 (TRPV1) channels in sympathetic nerve terminals, triggering norepinephrine release. This stimulates β3-adrenergic receptors in brown and white adipose tissue, activating uncoupling protein 1 (UCP1) to increase [thermogenesis](/ingredients/condition/weight-management). Unlike capsaicin, dihydrocapsiate bypasses vanilloid receptor desensitization, providing sustained metabolic enhancement without tolerance development.

## Clinical Summary

One small randomized controlled trial (n=12) demonstrated that CapsiAtra supplementation increased resting energy expenditure by 50 kcal/day compared to placebo. The study showed enhanced [fat oxidation](/ingredients/condition/weight-management) rates and improved substrate utilization during rest periods. However, evidence remains limited due to small sample size and lack of long-term weight loss data. Additional larger-scale trials are needed to confirm metabolic benefits and establish optimal dosing protocols.

## Nutritional Profile

CapsiAtra is a standardized extract of Capsicum annuum (sweet pepper) providing ≥2% dihydrocapsiate (DCT), a non-pungent capsaicinoid analog. Dihydrocapsiate (chemical formula: C₁₈H₂₆O₄, MW ~306.4 g/mol) is an ester of vanillyl alcohol and 8-methylnonanoic acid, structurally related to capsaicin but lacking the amide bond responsible for pungency. Typical commercial doses range from 3–9 mg dihydrocapsiate per day, with 6 mg/day being the most commonly studied dose for thermogenic effects. The extract itself is virtually devoid of macronutrients (negligible protein, fat, carbohydrate, and fiber at supplemental doses). It contains no significant vitamins or minerals at effective dosing levels. Key bioactive compound: Dihydrocapsiate (≥2% of extract weight; ~2–6 mg per typical serving of 100–300 mg extract). Minor related capsinoids may include nordihydrocapsiate and homodihydrocapsiate at trace levels (<0.5%). Bioavailability notes: Dihydrocapsiate is rapidly hydrolyzed in the gastrointestinal tract and intestinal mucosa by lipase and esterase enzymes, yielding vanillyl alcohol and a fatty acid chain. Despite extensive first-pass hydrolysis (oral bioavailability of intact dihydrocapsiate is very low, estimated <1% reaching systemic circulation unchanged), the compound activates TRPV1 (transient receptor potential vanilloid 1) receptors locally in the gut mucosa and afferent sensory neurons before degradation, which is believed to mediate its thermogenic signaling via sympathetic nervous system activation. The metabolite vanillyl alcohol is rapidly conjugated (glucuronidation/sulfation) and excreted. Peak plasma metabolite levels occur within 15–40 minutes post-ingestion. The ester bond hydrolysis distinguishes its pharmacokinetics from capsaicin (which has an amide bond resistant to rapid GI hydrolysis), explaining the absence of oral/gastric burning sensation. Fat co-ingestion may modestly slow hydrolysis but clinical significance is unclear. No known drug-nutrient interactions at standard doses. Caloric contribution at supplemental doses is effectively zero (<1 kcal).

## Dosage & Preparation

Clinically studied dose: 1 mg/day of pure dihydrocapsiate in capsules (diluted to 0.5% in refined rapeseed oil) for 4 weeks. CapsiAtra is marketed as a standardized extract with ≥98% purity, though specific dosing recommendations for commercial products are not established in clinical trials. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

CapsiAtra appears well-tolerated with minimal reported side effects, unlike capsaicin which causes gastrointestinal irritation. No significant drug interactions have been documented, though theoretical interactions with thermogenic compounds or [blood pressure](/ingredients/condition/heart-health) medications warrant caution. Individuals with cardiovascular conditions should consult healthcare providers before use due to potential sympathetic nervous system activation. Safety during pregnancy and lactation has not been established.

## Scientific Research

Clinical evidence for dihydrocapsiate is limited to one small randomized, double-blind, placebo-controlled crossover trial (n=12) showing a 50 kcal/day increase in resting energy expenditure over 4 weeks (PMC2954444). While CapsiAtra marketing references over 50 capsinoid studies, specific dihydrocapsiate RCTs beyond this single trial are not available, and trial NCT00999297 lacks accessible details.

## Historical & Cultural Context

Dihydrocapsiate was first isolated from CH-19 Sweet peppers by Yazawa et al. in 1989, with no documented traditional medicine use. Unlike capsaicin-containing peppers with extensive historical applications, capsinoids like DHC lack evidence of pre-modern use in traditional systems such as Ayurveda or TCM.

## Synergistic Combinations

Green tea extract (EGCG), L-carnitine, Chromium picolinate, Forskolin, Cayenne pepper extract

## Frequently Asked Questions

### How much does CapsiAtra increase metabolism?

Clinical research shows CapsiAtra increases resting energy expenditure by approximately 50 kcal/day. This represents a modest but measurable boost to baseline metabolic rate without causing digestive discomfort.

### What is the difference between CapsiAtra and capsaicin?

CapsiAtra (dihydrocapsiate) is a non-pungent capsaicinoid that provides metabolic benefits without the burning sensation or stomach irritation of capsaicin. Both activate TRPV1 receptors, but CapsiAtra avoids receptor desensitization for sustained effects.

### What is the recommended CapsiAtra dosage?

The clinical study used doses that increased energy expenditure by 50 kcal/day, though specific dosing protocols vary by manufacturer. Most supplements provide 3-9mg of dihydrocapsiate per serving based on available research.

### How long does it take for CapsiAtra to work?

CapsiAtra's thermogenic effects on metabolism can be measured within hours of supplementation. However, meaningful weight management results require consistent daily use combined with proper diet and exercise over several weeks.

### Can CapsiAtra cause side effects?

CapsiAtra is generally well-tolerated with minimal side effects reported in clinical studies. Unlike capsaicin, it does not cause gastrointestinal irritation, though individuals with heart conditions should use caution due to sympathetic nervous system activation.

### Is CapsiAtra safe to take with common weight loss medications?

CapsiAtra may have additive thermogenic effects when combined with stimulant-based weight loss drugs, which could increase heart rate or blood pressure; consult your healthcare provider before combining it with prescription weight loss medications or stimulants. There is limited clinical data on CapsiAtra interactions with specific medications, so medical supervision is recommended if you are taking other metabolic enhancers or cardiovascular drugs.

### Who should avoid CapsiAtra supplementation?

Individuals with uncontrolled hypertension, heart conditions, or those taking blood pressure medications should consult a doctor before using CapsiAtra due to its thermogenic effects. Pregnant and nursing women lack sufficient safety data and should avoid this ingredient, and it is not recommended for children without pediatric guidance.

### How strong is the clinical evidence supporting CapsiAtra's weight loss benefits?

The evidence for CapsiAtra is currently limited, based primarily on small-scale studies (such as a 12-person trial showing 50 kcal/day metabolic increase), which are too preliminary to draw firm conclusions about significant weight loss effects. While the TRPV1 receptor mechanism is scientifically plausible, larger, longer-term clinical trials are needed to establish whether CapsiAtra produces meaningful real-world weight management results compared to diet and exercise alone.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*